LONDON (Alliance News) - Drugmaker Hikma Pharmaceuticals PLC on Thursday said a Delaware court in the US has dismissed claims made against the UK-listed company by Takeda Pharmaceuticals US.
Takeda, the US subsidiary of Japan's Takeda Pharmaceutical Co Ltd, had made claims against Hikma alleging the infringement of patents covering Takeda's colchicine product, Colcrys.
Hikma has been selling its own colchicine product, Mitigare, since January 2015, and Takeda had claimed Hikma's West-Ward Pharmaceutical Corp subsidiary had infringed on its patents.
The product is used to treat gout inflammation.
The US District Court of the District of Delaware has ruled in Hikma favour in the dispute, the company said.
"I am very pleased with the ruling of the Delaware Court. This is a successful outcome and demonstrates our commitment to bringing more differentiated products to the US market," said Hikma Chairman and Chief Executive Said Darwazah.
Hikma shares were down 1.1% to 2,241.00 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Hikma Pharmaceuticals (HIK)